<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332019000400515</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Nimotuzumab y gemcitabina en el tratamiento del cáncer de páncreas y metástasis esplénica]]></article-title>
<article-title xml:lang="en"><![CDATA[Nimotuzumab and gemcitabine in the treatment of pancreatic cancer and splenic metastases]]></article-title>
<article-title xml:lang="pt"><![CDATA[Nimotuzumabe e gencitabina no tratamento do câncer de pâncreas e metástases esplênicas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piriz Momblant]]></surname>
<given-names><![CDATA[Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler Cano]]></surname>
<given-names><![CDATA[Dayami]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Puente]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Dr. Agostinho Neto&#8221;  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Nacional Coordinador de Ensayos Clínicos  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>98</volume>
<numero>4</numero>
<fpage>515</fpage>
<lpage>523</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332019000400515&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332019000400515&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332019000400515&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se presentó un paciente masculino de 69 años con una colestasis extrahepática, pérdida de peso, astenia y anorexia, antecedentes de pancreatitis crónica, diabetes mellitus e hipertensión arterial, el cual fue diagnosticado con adenocarcinoma de páncreas con metástasis esplénica. Se le realizó colecistoyeyunostomía con yeyunoyeyunostomía por ser irresecable el tumor. Fue incluido en el ensayo clínico IIC RD-EC166 y tratado con nimotuzumab y gemcitabina. En los estudios evolutivos no se apreciaron las imágenes metastásicas que se observaron antes del tratamiento lo que presupone la utilidad de estos fármacos para el control de éstas. No se encontraron referentes sobre el tema en la literatura nacional e internacional consultadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT A 69-year-old male patient presented with extrahepatic cholestasis, weight loss, asthenia and anorexia, a history of chronic pancreatitis, diabetes mellitus and arterial hypertension, who was diagnosed with adenocarcinoma of the pancreas with splenic metastases. A cholecystojejunostomy was performed with jejunum jejunostomy because the tumor was unresectable. It was included in the IIC RD-EC166 clinical trial and treated with nimotuzumab and gemcitabine. In the evolutionary studies the metastatic images that were observed before the treatment were not appreciated, which presupposes the usefulness of these drugs for their control. No references on the subject were found in the national and international literature consulted.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO Paciente do sexo masculino, 69 anos, apresentou colestase extra-hepática, perda de peso, astenia e anorexia, história de pancreatite crônica, diabetes mellitus e hipertensão arterial, diagnosticada com adenocarcinoma do pâncreas com metástases esplênicas. Uma colecistojejunostomia foi realizada com jejuno jejunostomia porque o tumor era irressecável. Foi incluído no ensaio clínico IIC RD-EC166 e tratado com nimotuzumab e gencitabina. Nos estudos evolutivos, as imagens metastáticas observadas antes do tratamento não foram apreciadas, o que pressupõe a utilidade desses medicamentos para seu controle. Não foram encontradas referências sobre o assunto na literatura nacional e internacional consultada]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[adenocarcinoma de páncreas]]></kwd>
<kwd lng="es"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="es"><![CDATA[gemcitabina]]></kwd>
<kwd lng="en"><![CDATA[pancreas adenocarcinoma]]></kwd>
<kwd lng="en"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="en"><![CDATA[gemcitabine]]></kwd>
<kwd lng="pt"><![CDATA[adenocarcinoma de pâncreas]]></kwd>
<kwd lng="pt"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="pt"><![CDATA[gemcitabina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ilic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ilic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of pancreatic cancer]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>9694-705</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rakszawski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vasekar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Passero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Saif]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology]]></article-title>
<source><![CDATA[Ther Adv Gastroenterol]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>141-51</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic tumors to the spleen. A 25-Year clinicopathologic study]]></article-title>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>2000</year>
<volume>124</volume>
<page-range>526-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Statistics, 2017]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2017</year>
<volume>67</volume>
<page-range>7-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsimponasa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsogiannia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crespoa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Diederichc]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Klosterhalfend]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Giagounidisa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature]]></article-title>
<source><![CDATA[Case Rep Oncol]]></source>
<year>2017</year>
<volume>10</volume>
<page-range>638-43</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence of splenic metastasis of carcinoma]]></article-title>
<source><![CDATA[Calif Med]]></source>
<year>1952</year>
<volume>76</volume>
<page-range>281-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nash]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sampson]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary carcinoma of the Spleen. Its Incidence in 544 Cases and a Review of the Literature]]></article-title>
<source><![CDATA[J Nat Med Assoc]]></source>
<year>1966</year>
<volume>58</volume>
<page-range>442-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramakrishnan]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Eswaraiah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Crombet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Piedra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Saurez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Iyer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arvind]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin]]></article-title>
<source><![CDATA[Landes Bioscience]]></source>
<year>2009</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Ministerio de Salud Pública</collab>
<article-title xml:lang=""><![CDATA[NIMOTUZUMAB]]></article-title>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>Ministerio de Salud Pública</collab>
<article-title xml:lang=""><![CDATA[CIMAher(r) (Nimotuzumab). Resumen de las Características del Producto]]></article-title>
<source><![CDATA[CECMED]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gemcitabina]]></article-title>
<source><![CDATA[Chemocare.com]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
